Horn Howard sold $117K of RARE

Horn Howard (Chief Financial Officer) sold 4,696 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $24.92 ($0.12M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Horn Howard
Published Aug 4, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RARE
Neutral
high confidence
Mentioned
$RARE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RARENeutralLow
01

Why it matters

The newest fact is the CFO’s planned open-market sale amount, price, and post-transaction holdings. It can be used for sentiment monitoring but does not introduce new fundamentals in the provided text.

02

Market read

Traders may note insider selling, but the 10b5-1 framing suggests limited incremental information content.

03

What to watch

The article provides only the sale details; it does not include any offsetting insider buys, changes in guidance, or operational/clinical updates that would justify a stronger trading view.

Relevance 3/10Novelty 3/10Timing: filed Aug 4, transaction dated Aug 3

Background

The article is a SEC Form 4 insider transaction disclosure for Ultragenyx Pharmaceutical Inc.

Company-level read

Ticker impact

$RARENeutralHigh confidence
Context

Ultragenyx CFO Horn Howard filed a Form 4 showing an open-market sale of 4,696 shares at $24.92 on Aug 3 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited and short-lived.

Evidence & confidence

The filing is a routine 10b5-1 planned sale by the CFO, with no accompanying guidance, deal, or regulatory/clinical catalyst in the text.

Market effects

Minimal. Insider 10b5-1 sales are common and do not, by themselves, signal sector-wide changes.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • Ultragenyx Pharmaceutical Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Horn Howard

    Chief Financial Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy

Ultragenyx Pharmaceutical Inc (RARE) discontinued two gene therapy programs (GTX-102 and UX701) due to efficacy and trial advancement issues. The company is restructuring, cutting 20% of its workforce. The future of setrusumab for osteogenesis imperfecta is uncertain pending FDA discussions. R&D spending for 2027 is guided at less than $350 million, with a focus on commercial products. The company faces potential competition in the Sanfilippo syndrome type A market.

$RAREHighAI 8/10

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx (RARE) reported Q3 2026 earnings, highlighting FDA approvals for GENGLYCOS and FAYUVI, two new gene therapies. The company also announced setbacks in clinical trials for GTX-102 and UX701, leading to program terminations and workforce reductions. Revenue guidance for 2026 was reaffirmed at $730M-$760M, with profitability expected in 2027. The company aims to reduce expenses by 50% by 2027.